Transition Pathway Brochure for IBD Patients

Written by: CDHF
Updated: November 30th, 2022
Helping Inflammatory Bowel Disease patients best understand transitioning/switching from a reference biologic to a biosimilar.

Related Articles:
View all News & Articles
Infliximab for the Treatment of Inflammatory Bowel Disease: An Overview of Drug History and Delivery


















































































